Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) from ProteoGenix; catalogue ARO-A23144; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) is a highly specific and potent antibody designed for the detection and neutralization of the Marburg and Ebola viruses. This powerful antibody targets the glycoprotein (GP1) of these deadly viruses, making it an essential tool for researchers and healthcare professionals working in the field of biotechnology.
The Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) works by binding to the GP1 protein on the surface of the Marburg and Ebola viruses. This binding prevents the viruses from entering and infecting host cells, effectively neutralizing their ability to cause harm. This antibody is capable of recognizing and binding to multiple strains of the Marburg and Ebola viruses, making it a versatile tool for various research and diagnostic applications.
The Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) has a wide range of applications in the field of biotechnology. Its primary use is in the development of diagnostic tests for the detection of Marburg and Ebola viruses. This antibody can also be utilized in the production of vaccines and therapeutics for these deadly diseases. Additionally, it can be used in research studies to understand the mechanisms of these viruses and develop effective treatments.
The Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) has been extensively used in various experimental studies to understand the biology and pathogenesis of Marburg and Ebola viruses. It has been used in in vitro studies to evaluate its neutralizing ability against different strains of these viruses. In vivo experiments have also shown promising results, demonstrating the potential of this antibody in the development of effective treatments and vaccines.
In conclusion, the Anti-MARV/EBOV Glycoprotein/GP1 Antibody (MR-72) is a highly specialized and effective tool for the detection and neutralization of Marburg and Ebola viruses. Its broad range of applications and proven efficacy in experimental studies make it an essential asset for any biotechnology research or diagnostic laboratory. Trust in the power of this antibody to aid in the fight against these deadly diseases. Order now and take the first step towards a safer and healthier future.
ProteoGenix catalogue number ARO-A23144. For research use only.
Target: Glycoprotein, GP1; Clonality: Monoclonal Antibody; Applications: ELISA, Neutralization.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Neutralization |
|---|---|---|---|---|---|---|---|---|---|
| Glycoprotein, GP1 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
